← All trials
NCT06757504
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 13, 2025
- Primary completion
- Feb 6, 2026
- Completion date
- May 8, 2026
- First posted
- Jan 3, 2025
- Last posted
- May 14, 2025
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Auzone Biological Technology Pty LtdLead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.